

Senti Biosciences Holdings, Inc. (SNTI)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001854270

Senti Biosciences Holdings, Inc.		
SNTI; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$51.2M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	short runway, thin data, degenerate inputs not computable: dilution, distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Apr 29, 2026 163 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$0.31 2026-10-08; market equity \$9.8M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Unless the context otherwise requires, for purposes of this section, the terms "we," "us," "our," "our Company," "the Company" or "Senti" refer to Senti Biosciences, Inc. and its subsidiaries. We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 17.9						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(24.1%)	(6.6%)	17.9	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 78.7						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(30.52)	(0.31)	80.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		1.67x	2.96x	77.0	839	2025-12-31
Growth and financing, sleeve percentile 96.3						
Revenue growth, three-year compound		(81.2%)	10.0%	98.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(34.3%)	2.1%	93.9	704	2025-12-31
Net share issuance, one year		not computable	2.5%			prior share count is 34 days earlier

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.0 months
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(73.2%)	8.0%	5
Distance from 52-week high	(86.5%)	(31.4%)	5

EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(435.6%)	(1.0%)	2
Book value to price	(0.34)	0.28	4
Sales to price	0.00	0.31	4
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.53)	(0.14)	5

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$6.5M
Operating cash flow, four quarters	-\$38.1M
Months of runway	2.0
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$60,347

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$61.4M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$43.4M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
3	assets	us-gaap:Assets	\$51.2M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
4	assets	us-gaap:Assets	\$97.8M	2024-12-31	2026-03-27	10-K	0001628280-26-021580
5	current assets	us-gaap:AssetsCurrent	\$23.3M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
6	current liabilities	us-gaap:LiabilitiesCurrent	\$14.0M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$358.6M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
8	operating income	us-gaap:OperatingIncomeLoss	-\$68.8M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
9	book equity	us-gaap:StockholdersEquity	\$5.6M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
10	liabilities	us-gaap:Liabilities	\$45.6M	2025-12-31	2026-03-27	10-K	0001628280-26-021580
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$22,000	2025-12-31	2026-03-27	10-K	0001628280-26-021580
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2024-12-31	2026-03-27	10-K	0001628280-26-021580
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.0M	2023-12-31	2025-03-20	10-K	0001854270-25-000042
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.3M	2022-12-31	2024-03-21	10-K	0001854270-24-000029
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$196,000	2025-12-31	2026-03-27	10-K	0001628280-26-021580
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$41.4M	2024-12-31	2026-03-27	10-K	0001628280-26-021580
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$26,000	2024-12-31	2026-03-27	10-K	0001628280-26-021580
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$52.4M	2023-12-31	2025-03-20	10-K	0001854270-25-000042
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12.0M	2023-12-31	2025-03-20	10-K	0001854270-25-000042
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$34.9M	2022-12-31	2024-03-21	10-K	0001854270-24-000029
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$41.4M	2022-12-31	2024-03-21	10-K	0001854270-24-000029
22	assets	us-gaap:Assets	\$119.5M	2023-12-31	2025-03-20	10-K	0001854270-25-000042
23	assets	us-gaap:Assets	\$180.8M	2022-12-31	2024-03-21	10-K	0001854270-24-000029
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,144,754	2026-04-22	2026-04-29	10-K/A	0001628280-26-028429
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,144,497	2026-03-19	2026-03-27	10-K	0001628280-26-021580